A narrative review on the use of Green synthesized metallic nanoparticles for targeted cancer therapy.

Bioorg Chem

ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Department of Clinical Oncology, Iran University of Medical Sciences, Tehran, Iran. Electronic address:

Published: February 2025

Cancer is a leading cause of death worldwide. While traditional and synthetic medical therapies are in place for cancer treatment, their effectiveness is hindered by various limitations, such as toxic side effects, limited availability, and high costs. In recent years, a promising alternative approach has emerged in the form of green-synthesized metallic nanoparticles (MNPs), which offer targeted cancer therapy. These nanoparticles (NPs) have garnered significant attention from cancer researchers owing to their natural or surface-induced anticancer properties, versatility of metals as agents, and eco-friendly nature. This approach may positively impact healthy cells surrounding the cancerous cells. Green-synthesized MNPs have gained popularity in cancer management because of their ease of handling in the laboratory and the affordability of starting materials compared to synthetic methods. This review analyzes green-synthesized MNPs for targeted cancer therapy, highlighting tumor-targeting strategies, synthesis methods, and clinical challenges. Unlike general reviews, it compares plant-, microbial-, and enzyme-mediated synthesis approaches, emphasizing their impact on nanoparticle stability, functionalization, and interactions with the tumor microenvironment for enhanced therapeutic efficacy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2025.108305DOI Listing

Publication Analysis

Top Keywords

targeted cancer
12
cancer therapy
12
metallic nanoparticles
8
green-synthesized mnps
8
cancer
7
narrative review
4
review green
4
green synthesized
4
synthesized metallic
4
nanoparticles targeted
4

Similar Publications

The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.

View Article and Find Full Text PDF

Photodynamic therapy (PDT) has been demonstrated to be an effective tool for cancer treatment. Seeking organelle-targeting photosensitizers (PSs) with robust reactive oxygen species (ROS) production is extremely in demand. Herein, we propose an aggregation-induced photosensitization strategy for effective PDT with osmium complexes.

View Article and Find Full Text PDF

Response to "The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes".

Clin Breast Cancer

February 2025

Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article and Find Full Text PDF

T-cell Engagers in Prostate Cancer.

Eur Urol

March 2025

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:

Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!